image credit: user6702303 / Freepik

Kyverna sets plans for IPO in test of biotech market

January 17, 2024


More than two years after the bottom fell out for biotech stocks, the market for IPOs is showing early signs of life, though investors are generally looking for more well-established companies than in the past. Four of the five companies who have filed for IPOs in January – including Kyverna – have drugs in Phase 2 testing or later.

Kyverna’s lead program is a CAR-T cell therapy called KYV-101 that originated within the NIH. Like many cell therapies for cancer, the treatment aims at a protein called CD19.

Read More on Biopharma Dive